Summary:
A phase 2 study of MLR-1023 as an adjunctive treatment to metformin for Type 2 Diabetes.
Qualified Participants Must:
Be between 18 and 75 years of age
Be diagnosed with Type 2 Diabetes, and currently taking metformin
Qualified Participants May Receive:
Compensation for time and travel, may receive investigational medication and study related treatment at no cost.